TP53 and bladder transitional cell carcinoma: Conversely, a wild-type TP53 gene expression signature in BLCA have been shown to be resistant to neoadjuvant chemotherapy 32, so the prognosis of patients in this cluster 4 may likely to be resistant to neoadjuvant chemotherapy.